Share-based Payment Arrangement, Expense of Larimar Therapeutics, Inc. from 31 Dec 2012 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Larimar Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2012 to 30 Sep 2025.
  • Larimar Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $1,785,000, a 8.8% decline year-over-year.
  • Larimar Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $7,857,000, a 5.4% decline year-over-year.
  • Larimar Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $8,796,000, a 16% increase from 2023.
  • Larimar Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $7,615,000, a 15% increase from 2022.
  • Larimar Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $6,619,000, a 21% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Larimar Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $7,857,000 $1,785,000 -$172,000 -8.8% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025 2025 Q3
Q2 2025 $8,029,000 $1,828,000 -$473,000 -21% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $8,502,000 $1,834,000 -$294,000 -14% 01 Jan 2025 31 Mar 2025 10-Q 30 Apr 2025 2025 Q1
Q4 2024 $8,796,000 $2,410,000 +$491,000 +26% 01 Oct 2024 31 Dec 2024 10-K 24 Mar 2025 2024 FY
Q3 2024 $8,305,000 $1,957,000 +$136,000 +7.5% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025 2025 Q3
Q2 2024 $8,169,000 $2,301,000 +$259,000 +13% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025 2025 Q2
Q1 2024 $7,910,000 $2,128,000 +$295,000 +16% 01 Jan 2024 31 Mar 2024 10-Q 30 Apr 2025 2025 Q1
Q4 2023 $7,615,000 $1,919,000 +$277,000 +17% 01 Oct 2023 31 Dec 2023 10-K 24 Mar 2025 2024 FY
Q3 2023 $7,338,000 $1,821,000 +$154,000 +9.2% 01 Jul 2023 30 Sep 2023 10-Q 30 Oct 2024 2024 Q3
Q2 2023 $7,184,000 $2,042,000 +$367,000 +22% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $6,817,000 $1,833,000 +$198,000 +12% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $6,619,000 $1,642,000 +$162,000 +11% 01 Oct 2022 31 Dec 2022 10-K 14 Mar 2024 2023 FY
Q3 2022 $6,457,000 $1,667,000 +$204,000 +14% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $6,253,000 $1,675,000 +$325,000 +24% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $5,928,000 $1,635,000 +$455,000 +39% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q4 2021 $5,473,000 $1,480,000 +$470,000 +47% 01 Oct 2021 31 Dec 2021 10-K 14 Mar 2023 2022 FY
Q3 2021 $5,003,000 $1,463,000 +$1,093,000 +295% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $3,910,000 $1,350,000 +$598,000 +80% 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $3,312,000 $1,180,000 +$1,151,000 +3969% 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q4 2020 $2,161,000 $1,010,000 +$3,022,000 01 Oct 2020 31 Dec 2020 10-K 25 Mar 2022 2021 FY
Q3 2020 $861,000 $370,000 +$338,000 +1056% 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021 2021 Q3
Q2 2020 $1,199,000 $752,000 +$719,000 +2179% 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2021 Q2
Q1 2020 $1,918,000 $29,000 -$2,047,000 -99% 01 Jan 2020 31 Mar 2020 10-Q 10 May 2021 2021 Q1
Q4 2019 $129,000 $2,012,000 -$4,302,000 -188% 01 Oct 2019 31 Dec 2019 10-K 04 Mar 2021 2020 FY
Q3 2019 $4,431,000 $32,000 -$2,168,000 -99% 01 Jul 2019 30 Sep 2019 10-Q 12 Nov 2020 2020 Q3
Q2 2019 $6,599,000 $33,000 -$2,638,000 -99% 01 Apr 2019 30 Jun 2019 10-Q 14 Aug 2020 2020 Q2
Q1 2019 $9,237,000 $2,076,000 -$390,000 -16% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q4 2018 $9,627,000 $2,290,000 +$188,000 +8.9% 01 Oct 2018 31 Dec 2018 10-K 05 Mar 2020 2019 FY
Q3 2018 $9,439,000 $2,200,000 +$104,000 +5% 01 Jul 2018 30 Sep 2018 10-Q 06 Nov 2019 2019 Q3
Q2 2018 $9,335,000 $2,671,000 +$569,000 +27% 01 Apr 2018 30 Jun 2018 10-Q 08 Aug 2019 2019 Q2
Q1 2018 $8,766,000 $2,466,000 +$465,000 +23% 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019 2019 Q1
Q4 2017 $8,301,000 $2,102,000 +$95,000 +4.7% 01 Oct 2017 31 Dec 2017 10-K 05 Mar 2020 2019 FY
Q3 2017 $8,206,000 $2,096,000 -$220,000 -9.5% 01 Jul 2017 30 Sep 2017 10-Q 09 Nov 2018 2018 Q3
Q2 2017 $8,426,000 $2,102,000 -$752,000 -26% 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018 2018 Q2
Q1 2017 $9,178,000 $2,001,000 -$755,000 -27% 01 Jan 2017 31 Mar 2017 10-Q 09 May 2017 2017 Q1
Q4 2016 $9,933,000 $2,007,000 -$738,000 -27% 01 Oct 2016 31 Dec 2016 10-K 14 Mar 2019 2018 FY
Q3 2016 $10,671,000 $2,316,000 -$525,000 -18% 01 Jul 2016 30 Sep 2016 10-Q 07 Nov 2017 2017 Q3
Q2 2016 $11,196,000 $2,854,000 +$915,000 +47% 01 Apr 2016 30 Jun 2016 10-Q 09 Aug 2017 2017 Q2
Q1 2016 $10,281,000 $2,756,000 +$1,699,000 +161% 01 Jan 2016 31 Mar 2016 10-Q 09 May 2017 2017 Q1
Q4 2015 $8,582,000 $2,745,000 +$2,102,000 +327% 01 Oct 2015 31 Dec 2015 10-K 09 Mar 2018 2017 FY
Q3 2015 $6,480,000 $2,841,000 +$2,375,000 +510% 01 Jul 2015 30 Sep 2015 10-Q 09 Nov 2016 2016 Q3
Q2 2015 $4,105,000 $1,939,000 +$1,671,000 +624% 01 Apr 2015 30 Jun 2015 10-Q 05 Aug 2016 2016 Q2
Q1 2015 $2,434,000 $1,057,000 +$881,000 +501% 01 Jan 2015 31 Mar 2015 10-Q 10 May 2016 2016 Q1
Q4 2014 $1,553,000 $643,000 01 Oct 2014 31 Dec 2014 10-K 10 Mar 2017 2016 FY
Q3 2014 $466,000 +$367,000 +371% 01 Jul 2014 30 Sep 2014 10-Q 13 Nov 2015 2015 Q3
Q2 2014 $268,000 +$165,000 +160% 01 Apr 2014 30 Jun 2014 10-Q 14 Aug 2015 2015 Q2
Q1 2014 $176,000 01 Jan 2014 31 Mar 2014 10-Q 14 May 2015 2015 Q1
Q3 2013 $99,000 01 Jul 2013 30 Sep 2013 10-Q 13 Nov 2014 2014 Q3
Q2 2013 $103,000 01 Apr 2013 30 Jun 2013 10-Q 14 Aug 2014 2014 Q2

Larimar Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $8,796,000 +$1,181,000 +16% 01 Jan 2024 31 Dec 2024 10-K 24 Mar 2025 2024 FY
2023 $7,615,000 +$996,000 +15% 01 Jan 2023 31 Dec 2023 10-K 24 Mar 2025 2024 FY
2022 $6,619,000 +$1,146,000 +21% 01 Jan 2022 31 Dec 2022 10-K 14 Mar 2024 2023 FY
2021 $5,473,000 +$3,312,000 +153% 01 Jan 2021 31 Dec 2021 10-K 14 Mar 2023 2022 FY
2020 $2,161,000 +$2,032,000 +1575% 01 Jan 2020 31 Dec 2020 10-K 25 Mar 2022 2021 FY
2019 $129,000 -$9,498,000 -99% 01 Jan 2019 31 Dec 2019 10-K 04 Mar 2021 2020 FY
2018 $9,627,000 +$1,326,000 +16% 01 Jan 2018 31 Dec 2018 10-K 05 Mar 2020 2019 FY
2017 $8,301,000 -$1,632,000 -16% 01 Jan 2017 31 Dec 2017 10-K 05 Mar 2020 2019 FY
2016 $9,933,000 +$1,351,000 +16% 01 Jan 2016 31 Dec 2016 10-K 14 Mar 2019 2018 FY
2015 $8,582,000 +$7,029,000 +453% 01 Jan 2015 31 Dec 2015 10-K 09 Mar 2018 2017 FY
2014 $1,553,000 +$1,158,000 +293% 01 Jan 2014 31 Dec 2014 10-K 10 Mar 2017 2016 FY
2013 $395,000 +$274,000 +226% 01 Jan 2013 31 Dec 2013 10-K 15 Mar 2016 2015 FY
2012 $121,000 01 Jan 2012 31 Dec 2012 10-K 25 Mar 2015 2014 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.